| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gait | 169 | 2023 | 411 | 26.890 |
Why?
|
| Parkinson Disease | 138 | 2023 | 846 | 23.980 |
Why?
|
| Gait Disorders, Neurologic | 76 | 2022 | 138 | 20.980 |
Why?
|
| Accidental Falls | 71 | 2022 | 113 | 16.590 |
Why?
|
| Walking | 99 | 2023 | 261 | 16.340 |
Why?
|
| Postural Balance | 56 | 2023 | 122 | 10.800 |
Why?
|
| Psychomotor Performance | 33 | 2021 | 213 | 6.670 |
Why?
|
| Wearable Electronic Devices | 16 | 2023 | 44 | 6.180 |
Why?
|
| Aged | 230 | 2023 | 9343 | 5.970 |
Why?
|
| Aging | 54 | 2023 | 1578 | 5.310 |
Why?
|
| Cognition | 48 | 2023 | 1378 | 5.100 |
Why?
|
| Humans | 332 | 2023 | 28548 | 4.950 |
Why?
|
| Male | 228 | 2023 | 15399 | 4.660 |
Why?
|
| Female | 228 | 2023 | 15818 | 4.570 |
Why?
|
| Attention | 27 | 2022 | 138 | 4.430 |
Why?
|
| Accelerometry | 20 | 2021 | 87 | 4.300 |
Why?
|
| Monitoring, Physiologic | 10 | 2022 | 77 | 3.880 |
Why?
|
| Aged, 80 and over | 110 | 2023 | 4901 | 3.870 |
Why?
|
| Activities of Daily Living | 25 | 2023 | 612 | 3.750 |
Why?
|
| Transcranial Direct Current Stimulation | 7 | 2022 | 9 | 3.720 |
Why?
|
| Middle Aged | 128 | 2023 | 9320 | 3.440 |
Why?
|
| Executive Function | 17 | 2022 | 116 | 3.140 |
Why?
|
| Cognition Disorders | 20 | 2022 | 1019 | 3.050 |
Why?
|
| Exercise Therapy | 17 | 2023 | 98 | 3.030 |
Why?
|
| Prefrontal Cortex | 14 | 2023 | 149 | 2.870 |
Why?
|
| Multiple Sclerosis | 8 | 2023 | 108 | 2.740 |
Why?
|
| Geriatric Assessment | 19 | 2020 | 214 | 2.620 |
Why?
|
| Exercise Test | 16 | 2023 | 122 | 2.520 |
Why?
|
| Task Performance and Analysis | 14 | 2021 | 49 | 2.490 |
Why?
|
| Reaction Time | 14 | 2020 | 114 | 2.380 |
Why?
|
| Functional Laterality | 12 | 2017 | 68 | 2.330 |
Why?
|
| Virtual Reality | 8 | 2022 | 13 | 2.250 |
Why?
|
| Neuropsychological Tests | 35 | 2022 | 1255 | 2.210 |
Why?
|
| Risk Assessment | 20 | 2022 | 676 | 2.200 |
Why?
|
| Tremor | 8 | 2020 | 117 | 2.160 |
Why?
|
| Mobility Limitation | 19 | 2020 | 95 | 2.080 |
Why?
|
| Motor Activity | 12 | 2020 | 330 | 2.030 |
Why?
|
| Physical Therapy Modalities | 14 | 2023 | 75 | 2.020 |
Why?
|
| Adult | 75 | 2022 | 8172 | 1.980 |
Why?
|
| Cross-Sectional Studies | 32 | 2023 | 934 | 1.860 |
Why?
|
| Algorithms | 16 | 2019 | 380 | 1.790 |
Why?
|
| Heart Rate | 21 | 2019 | 117 | 1.750 |
Why?
|
| Locomotion | 8 | 2017 | 24 | 1.740 |
Why?
|
| Exercise | 13 | 2023 | 472 | 1.730 |
Why?
|
| Brain | 15 | 2022 | 1696 | 1.700 |
Why?
|
| Machine Learning | 8 | 2023 | 72 | 1.650 |
Why?
|
| Periodicity | 7 | 2008 | 11 | 1.590 |
Why?
|
| Nerve Net | 6 | 2021 | 46 | 1.570 |
Why?
|
| Severity of Illness Index | 20 | 2022 | 990 | 1.560 |
Why?
|
| Movement | 10 | 2020 | 118 | 1.530 |
Why?
|
| Monitoring, Ambulatory | 7 | 2017 | 19 | 1.460 |
Why?
|
| Motor Cortex | 5 | 2021 | 17 | 1.430 |
Why?
|
| Walking Speed | 10 | 2023 | 40 | 1.310 |
Why?
|
| Posture | 10 | 2018 | 68 | 1.300 |
Why?
|
| Biomechanical Phenomena | 21 | 2022 | 676 | 1.290 |
Why?
|
| Stroke | 7 | 2022 | 276 | 1.290 |
Why?
|
| Signal Processing, Computer-Assisted | 10 | 2019 | 33 | 1.230 |
Why?
|
| Tai Ji | 8 | 2023 | 9 | 1.230 |
Why?
|
| Cognitive Dysfunction | 10 | 2023 | 1073 | 1.220 |
Why?
|
| User-Computer Interface | 5 | 2016 | 20 | 1.200 |
Why?
|
| Acceleration | 8 | 2016 | 21 | 1.200 |
Why?
|
| Quality of Life | 16 | 2022 | 659 | 1.170 |
Why?
|
| Risk Factors | 32 | 2020 | 2414 | 1.140 |
Why?
|
| Hypokinesia | 6 | 2020 | 23 | 1.130 |
Why?
|
| Orthotic Devices | 5 | 2009 | 24 | 1.090 |
Why?
|
| Case-Control Studies | 20 | 2019 | 599 | 1.090 |
Why?
|
| Subthalamic Nucleus | 3 | 2017 | 19 | 1.050 |
Why?
|
| Pilot Projects | 15 | 2022 | 438 | 1.040 |
Why?
|
| Models, Biological | 9 | 2015 | 329 | 1.040 |
Why?
|
| Time Factors | 25 | 2019 | 1497 | 1.010 |
Why?
|
| Feedback, Sensory | 4 | 2018 | 7 | 1.010 |
Why?
|
| Electric Stimulation Therapy | 4 | 2009 | 43 | 1.010 |
Why?
|
| Freezing Reaction, Cataleptic | 3 | 2018 | 3 | 0.980 |
Why?
|
| Antiparkinson Agents | 11 | 2014 | 66 | 0.970 |
Why?
|
| Motor Skills | 4 | 2018 | 53 | 0.960 |
Why?
|
| Fractals | 11 | 2017 | 21 | 0.950 |
Why?
|
| Huntington Disease | 9 | 2022 | 51 | 0.920 |
Why?
|
| Independent Living | 9 | 2022 | 320 | 0.910 |
Why?
|
| Young Adult | 16 | 2022 | 2103 | 0.910 |
Why?
|
| Methylphenidate | 6 | 2009 | 8 | 0.880 |
Why?
|
| Deep Brain Stimulation | 3 | 2017 | 39 | 0.870 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 2 | 2023 | 24 | 0.860 |
Why?
|
| Central Nervous System Stimulants | 6 | 2009 | 41 | 0.850 |
Why?
|
| Gait Ataxia | 3 | 2013 | 5 | 0.840 |
Why?
|
| Ataxia | 6 | 2017 | 78 | 0.830 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2021 | 1197 | 0.820 |
Why?
|
| Virtual Reality Exposure Therapy | 4 | 2017 | 7 | 0.820 |
Why?
|
| Levodopa | 8 | 2020 | 47 | 0.810 |
Why?
|
| Fear | 5 | 2016 | 48 | 0.790 |
Why?
|
| Disability Evaluation | 7 | 2019 | 291 | 0.790 |
Why?
|
| Transcranial Magnetic Stimulation | 3 | 2021 | 17 | 0.790 |
Why?
|
| Frailty | 4 | 2023 | 35 | 0.780 |
Why?
|
| Blood Pressure | 7 | 2020 | 207 | 0.770 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 4 | 2018 | 37 | 0.760 |
Why?
|
| Time and Motion Studies | 4 | 2021 | 18 | 0.760 |
Why?
|
| Fatigue | 3 | 2019 | 64 | 0.760 |
Why?
|
| Paresis | 5 | 2014 | 17 | 0.760 |
Why?
|
| Depression | 5 | 2018 | 454 | 0.750 |
Why?
|
| Problem Solving | 8 | 2012 | 47 | 0.730 |
Why?
|
| Risk | 9 | 2018 | 207 | 0.730 |
Why?
|
| Frontal Lobe | 4 | 2018 | 83 | 0.720 |
Why?
|
| Brain Mapping | 6 | 2020 | 167 | 0.720 |
Why?
|
| Double-Blind Method | 7 | 2021 | 433 | 0.710 |
Why?
|
| Cognitive Reserve | 2 | 2018 | 39 | 0.700 |
Why?
|
| Martial Arts | 1 | 2020 | 4 | 0.680 |
Why?
|
| Swimming | 1 | 2020 | 7 | 0.680 |
Why?
|
| Muscle Rigidity | 2 | 2019 | 21 | 0.680 |
Why?
|
| Arm | 3 | 2016 | 84 | 0.670 |
Why?
|
| Disabled Persons | 4 | 2023 | 125 | 0.670 |
Why?
|
| Avoidance Learning | 1 | 2019 | 6 | 0.670 |
Why?
|
| Pattern Recognition, Automated | 1 | 2019 | 7 | 0.670 |
Why?
|
| Statistics, Nonparametric | 8 | 2017 | 129 | 0.660 |
Why?
|
| Sensation Disorders | 2 | 2013 | 11 | 0.660 |
Why?
|
| Follow-Up Studies | 12 | 2020 | 1863 | 0.650 |
Why?
|
| Reproducibility of Results | 15 | 2022 | 732 | 0.640 |
Why?
|
| Torso | 2 | 2016 | 7 | 0.640 |
Why?
|
| Laboratories | 1 | 2019 | 9 | 0.640 |
Why?
|
| Prospective Studies | 17 | 2022 | 1811 | 0.640 |
Why?
|
| Extremities | 3 | 2017 | 28 | 0.620 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 129 | 0.610 |
Why?
|
| Treatment Outcome | 16 | 2018 | 3622 | 0.600 |
Why?
|
| Age Factors | 12 | 2019 | 789 | 0.600 |
Why?
|
| Longitudinal Studies | 14 | 2023 | 1397 | 0.580 |
Why?
|
| Self Report | 4 | 2022 | 226 | 0.570 |
Why?
|
| Spectroscopy, Near-Infrared | 8 | 2021 | 10 | 0.570 |
Why?
|
| Ischemic Attack, Transient | 2 | 2015 | 18 | 0.570 |
Why?
|
| Acoustic Stimulation | 5 | 2018 | 56 | 0.570 |
Why?
|
| Learning | 3 | 2019 | 71 | 0.560 |
Why?
|
| Chronic Pain | 4 | 2020 | 114 | 0.560 |
Why?
|
| Dementia | 5 | 2022 | 582 | 0.550 |
Why?
|
| Caudate Nucleus | 2 | 2018 | 11 | 0.540 |
Why?
|
| Foot | 4 | 2020 | 45 | 0.540 |
Why?
|
| Telemetry | 2 | 2013 | 11 | 0.530 |
Why?
|
| Analysis of Variance | 8 | 2012 | 276 | 0.520 |
Why?
|
| Alzheimer Disease | 7 | 2023 | 2144 | 0.520 |
Why?
|
| Neurologic Examination | 9 | 2021 | 115 | 0.510 |
Why?
|
| Medical Informatics Applications | 1 | 2015 | 1 | 0.510 |
Why?
|
| Biomedical Engineering | 1 | 2015 | 5 | 0.510 |
Why?
|
| Movement Disorders | 4 | 2020 | 91 | 0.490 |
Why?
|
| Uncertainty | 1 | 2015 | 9 | 0.490 |
Why?
|
| Cerebral Cortex | 2 | 2018 | 165 | 0.480 |
Why?
|
| Electroencephalography | 6 | 2022 | 80 | 0.480 |
Why?
|
| Residence Characteristics | 2 | 2016 | 214 | 0.480 |
Why?
|
| Memory | 8 | 2019 | 311 | 0.460 |
Why?
|
| Mutation | 4 | 2018 | 352 | 0.460 |
Why?
|
| Neurons | 1 | 2017 | 341 | 0.450 |
Why?
|
| Nerve Fibers, Unmyelinated | 1 | 2013 | 4 | 0.440 |
Why?
|
| Smartphone | 3 | 2019 | 17 | 0.430 |
Why?
|
| Cross-Over Studies | 3 | 2022 | 63 | 0.420 |
Why?
|
| Myelin Sheath | 1 | 2013 | 26 | 0.410 |
Why?
|
| Reference Values | 10 | 2012 | 201 | 0.410 |
Why?
|
| Parkinsonian Disorders | 4 | 2021 | 227 | 0.410 |
Why?
|
| Connectome | 3 | 2021 | 12 | 0.410 |
Why?
|
| Thinking | 2 | 2010 | 18 | 0.410 |
Why?
|
| Neuroimaging | 4 | 2020 | 133 | 0.400 |
Why?
|
| Wireless Technology | 1 | 2011 | 2 | 0.390 |
Why?
|
| Remote Sensing Technology | 1 | 2011 | 3 | 0.390 |
Why?
|
| Musculoskeletal Pain | 2 | 2023 | 21 | 0.390 |
Why?
|
| Cues | 4 | 2018 | 50 | 0.390 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2023 | 23 | 0.380 |
Why?
|
| Cohort Studies | 11 | 2020 | 1942 | 0.380 |
Why?
|
| Biofeedback, Psychology | 1 | 2011 | 4 | 0.380 |
Why?
|
| Stereotyping | 3 | 2008 | 16 | 0.380 |
Why?
|
| Autonomic Nervous System | 3 | 2009 | 19 | 0.370 |
Why?
|
| Hypertension | 4 | 2020 | 244 | 0.370 |
Why?
|
| Adolescent | 11 | 2019 | 2322 | 0.370 |
Why?
|
| Dopamine | 2 | 2020 | 87 | 0.370 |
Why?
|
| Mental Status Schedule | 5 | 2017 | 97 | 0.360 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2020 | 329 | 0.360 |
Why?
|
| Multitasking Behavior | 3 | 2020 | 3 | 0.360 |
Why?
|
| Models, Statistical | 6 | 2020 | 129 | 0.360 |
Why?
|
| Evoked Potentials | 2 | 2021 | 14 | 0.350 |
Why?
|
| Axis, Cervical Vertebra | 1 | 2010 | 9 | 0.350 |
Why?
|
| Neurological Rehabilitation | 2 | 2020 | 5 | 0.350 |
Why?
|
| Heterozygote | 1 | 2011 | 102 | 0.350 |
Why?
|
| Health Status Indicators | 2 | 2008 | 75 | 0.350 |
Why?
|
| Patient Outcome Assessment | 3 | 2019 | 41 | 0.350 |
Why?
|
| Central Nervous System | 4 | 2017 | 59 | 0.340 |
Why?
|
| Adaptation, Physiological | 4 | 2018 | 53 | 0.340 |
Why?
|
| Eye Movements | 3 | 2020 | 12 | 0.340 |
Why?
|
| Electrocardiography | 9 | 2010 | 119 | 0.330 |
Why?
|
| Geriatrics | 2 | 2007 | 9 | 0.330 |
Why?
|
| Dominance, Cerebral | 1 | 2009 | 16 | 0.320 |
Why?
|
| Mobile Applications | 3 | 2019 | 32 | 0.320 |
Why?
|
| Orientation | 2 | 2013 | 6 | 0.320 |
Why?
|
| Artificial Limbs | 1 | 2009 | 7 | 0.320 |
Why?
|
| Predictive Value of Tests | 7 | 2013 | 496 | 0.310 |
Why?
|
| Neural Pathways | 4 | 2020 | 73 | 0.310 |
Why?
|
| Linear Models | 5 | 2017 | 255 | 0.310 |
Why?
|
| Brain Injuries | 1 | 2009 | 36 | 0.310 |
Why?
|
| Statistics as Topic | 6 | 2017 | 112 | 0.300 |
Why?
|
| Exercise Tolerance | 2 | 2007 | 32 | 0.300 |
Why?
|
| Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 4 | 2018 | 5 | 0.290 |
Why?
|
| Attitude to Health | 2 | 2017 | 105 | 0.290 |
Why?
|
| Touch | 1 | 2007 | 9 | 0.290 |
Why?
|
| Biological Clocks | 1 | 2007 | 17 | 0.280 |
Why?
|
| Early Diagnosis | 3 | 2013 | 67 | 0.280 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2017 | 190 | 0.280 |
Why?
|
| Stroop Test | 2 | 2018 | 3 | 0.280 |
Why?
|
| Hearing | 1 | 2007 | 21 | 0.280 |
Why?
|
| Feedback | 1 | 2007 | 33 | 0.280 |
Why?
|
| Mental Processes | 2 | 2006 | 20 | 0.280 |
Why?
|
| Health Status | 5 | 2016 | 226 | 0.280 |
Why?
|
| Telemedicine | 2 | 2020 | 119 | 0.280 |
Why?
|
| Boston | 7 | 2019 | 27 | 0.280 |
Why?
|
| Logistic Models | 6 | 2018 | 398 | 0.280 |
Why?
|
| Physical Fitness | 5 | 2019 | 57 | 0.270 |
Why?
|
| Muscle, Skeletal | 4 | 2021 | 398 | 0.270 |
Why?
|
| Shoes | 2 | 2017 | 33 | 0.270 |
Why?
|
| Feasibility Studies | 5 | 2016 | 233 | 0.270 |
Why?
|
| Antidepressive Agents | 1 | 2007 | 97 | 0.270 |
Why?
|
| Stress, Psychological | 2 | 2011 | 242 | 0.270 |
Why?
|
| Neurodegenerative Diseases | 2 | 2019 | 124 | 0.260 |
Why?
|
| Sex Factors | 7 | 2019 | 477 | 0.260 |
Why?
|
| Sensation | 3 | 2011 | 11 | 0.260 |
Why?
|
| Knee Joint | 4 | 2022 | 756 | 0.260 |
Why?
|
| Regression Analysis | 5 | 2015 | 270 | 0.250 |
Why?
|
| Basal Ganglia | 3 | 2020 | 16 | 0.250 |
Why?
|
| Heart Failure | 8 | 2001 | 179 | 0.250 |
Why?
|
| Biomarkers | 3 | 2018 | 601 | 0.250 |
Why?
|
| Space Perception | 2 | 2020 | 24 | 0.240 |
Why?
|
| Incidence | 4 | 2021 | 774 | 0.240 |
Why?
|
| Range of Motion, Articular | 3 | 2019 | 725 | 0.230 |
Why?
|
| Demography | 3 | 2014 | 74 | 0.230 |
Why?
|
| Multivariate Analysis | 6 | 2016 | 333 | 0.230 |
Why?
|
| Chorea | 2 | 2022 | 5 | 0.230 |
Why?
|
| Prognosis | 6 | 2019 | 827 | 0.230 |
Why?
|
| Patient Satisfaction | 4 | 2013 | 329 | 0.230 |
Why?
|
| Sleep | 2 | 2020 | 355 | 0.230 |
Why?
|
| Bipolar Disorder | 1 | 2004 | 132 | 0.220 |
Why?
|
| Depressive Disorder, Major | 1 | 2004 | 103 | 0.220 |
Why?
|
| Cerebellum | 3 | 2020 | 47 | 0.220 |
Why?
|
| Kinetics | 4 | 2018 | 194 | 0.220 |
Why?
|
| Muscle Contraction | 2 | 2021 | 68 | 0.220 |
Why?
|
| Neck Pain | 1 | 2023 | 28 | 0.210 |
Why?
|
| Thalamus | 2 | 2020 | 16 | 0.210 |
Why?
|
| Myoclonic Epilepsy, Juvenile | 1 | 2023 | 1 | 0.210 |
Why?
|
| Gray Matter | 2 | 2020 | 55 | 0.210 |
Why?
|
| Research Design | 3 | 2022 | 207 | 0.210 |
Why?
|
| Chiropractic | 1 | 2022 | 1 | 0.210 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 40 | 0.200 |
Why?
|
| Wrist | 1 | 2022 | 17 | 0.200 |
Why?
|
| Disease Progression | 3 | 2017 | 722 | 0.200 |
Why?
|
| Surveys and Questionnaires | 6 | 2019 | 1213 | 0.200 |
Why?
|
| Caregivers | 2 | 2022 | 203 | 0.200 |
Why?
|
| Mental Health | 2 | 2001 | 123 | 0.200 |
Why?
|
| Putamen | 3 | 2018 | 21 | 0.200 |
Why?
|
| Therapy, Computer-Assisted | 2 | 2014 | 11 | 0.200 |
Why?
|
| Basal Ganglia Diseases | 2 | 2000 | 6 | 0.200 |
Why?
|
| Stochastic Processes | 1 | 2001 | 13 | 0.190 |
Why?
|
| Comorbidity | 5 | 2016 | 500 | 0.190 |
Why?
|
| Brain Ischemia | 1 | 2022 | 63 | 0.190 |
Why?
|
| Nonlinear Dynamics | 5 | 2009 | 13 | 0.190 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 53 | 0.190 |
Why?
|
| Healthy Volunteers | 2 | 2019 | 44 | 0.190 |
Why?
|
| Child | 5 | 2018 | 1424 | 0.190 |
Why?
|
| Equipment Design | 5 | 2017 | 155 | 0.190 |
Why?
|
| Homeostasis | 3 | 2020 | 68 | 0.190 |
Why?
|
| Brain Waves | 1 | 2021 | 5 | 0.190 |
Why?
|
| Essential Tremor | 1 | 2021 | 5 | 0.190 |
Why?
|
| Lewy Body Disease | 1 | 2022 | 100 | 0.190 |
Why?
|
| Telerehabilitation | 1 | 2021 | 4 | 0.190 |
Why?
|
| Eye Movement Measurements | 2 | 2018 | 2 | 0.180 |
Why?
|
| Minority Groups | 1 | 2001 | 87 | 0.180 |
Why?
|
| Lower Extremity | 1 | 2021 | 40 | 0.180 |
Why?
|
| Paraplegia | 2 | 1991 | 6 | 0.180 |
Why?
|
| Social Class | 1 | 2001 | 67 | 0.180 |
Why?
|
| Anticipation, Psychological | 1 | 2020 | 5 | 0.180 |
Why?
|
| Ankle | 1 | 2020 | 24 | 0.170 |
Why?
|
| Quality of Health Care | 1 | 2001 | 127 | 0.170 |
Why?
|
| Stroke Rehabilitation | 2 | 2011 | 23 | 0.170 |
Why?
|
| Cardiovascular Diseases | 2 | 2001 | 373 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2001 | 244 | 0.170 |
Why?
|
| Walk Test | 1 | 2019 | 9 | 0.170 |
Why?
|
| Computer Graphics | 2 | 2013 | 6 | 0.170 |
Why?
|
| Prejudice | 1 | 1999 | 34 | 0.160 |
Why?
|
| Sensitivity and Specificity | 6 | 2012 | 520 | 0.160 |
Why?
|
| Weight-Bearing | 2 | 2017 | 171 | 0.160 |
Why?
|
| Nervous System Diseases | 4 | 2019 | 121 | 0.160 |
Why?
|
| Event-Related Potentials, P300 | 1 | 2018 | 2 | 0.160 |
Why?
|
| Health | 2 | 2017 | 10 | 0.160 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2005 | 327 | 0.160 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2018 | 11 | 0.160 |
Why?
|
| Athletes | 1 | 2019 | 89 | 0.160 |
Why?
|
| Mental Recall | 2 | 2009 | 71 | 0.150 |
Why?
|
| Magnetic Phenomena | 1 | 2018 | 1 | 0.150 |
Why?
|
| Auditory Perception | 1 | 2018 | 43 | 0.150 |
Why?
|
| Fixation, Ocular | 1 | 2018 | 3 | 0.150 |
Why?
|
| Software | 2 | 2013 | 68 | 0.150 |
Why?
|
| Osteoarthritis, Knee | 1 | 2022 | 361 | 0.150 |
Why?
|
| Models, Cardiovascular | 4 | 2009 | 15 | 0.150 |
Why?
|
| Circadian Rhythm | 1 | 2021 | 298 | 0.150 |
Why?
|
| Neuronal Plasticity | 1 | 2018 | 47 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2022 | 392 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 772 | 0.150 |
Why?
|
| Qigong | 1 | 2017 | 1 | 0.140 |
Why?
|
| Education | 1 | 2017 | 46 | 0.140 |
Why?
|
| Psychometrics | 2 | 2010 | 244 | 0.140 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1997 | 37 | 0.140 |
Why?
|
| Survival Analysis | 3 | 2012 | 267 | 0.140 |
Why?
|
| United States | 6 | 2020 | 2188 | 0.140 |
Why?
|
| Galvanic Skin Response | 2 | 2015 | 7 | 0.140 |
Why?
|
| Communication Barriers | 1 | 2016 | 4 | 0.140 |
Why?
|
| Corpus Striatum | 1 | 2017 | 65 | 0.140 |
Why?
|
| Video Recording | 2 | 2013 | 35 | 0.140 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2015 | 11 | 0.130 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 1997 | 63 | 0.130 |
Why?
|
| Prodromal Symptoms | 1 | 2016 | 18 | 0.130 |
Why?
|
| Mexican Americans | 1 | 2016 | 29 | 0.130 |
Why?
|
| Species Specificity | 1 | 2016 | 42 | 0.130 |
Why?
|
| Pain Measurement | 4 | 2020 | 472 | 0.130 |
Why?
|
| Formative Feedback | 1 | 2016 | 3 | 0.130 |
Why?
|
| Prosthesis Design | 2 | 2009 | 503 | 0.130 |
Why?
|
| Bone Density | 1 | 2017 | 149 | 0.130 |
Why?
|
| Electrodes | 1 | 2015 | 12 | 0.130 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1995 | 3 | 0.120 |
Why?
|
| Hypotension, Orthostatic | 1 | 1995 | 11 | 0.120 |
Why?
|
| Electronics | 1 | 1995 | 11 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 196 | 0.120 |
Why?
|
| Observer Variation | 2 | 2013 | 104 | 0.120 |
Why?
|
| Rotation | 1 | 2015 | 142 | 0.120 |
Why?
|
| Data Interpretation, Statistical | 3 | 2013 | 84 | 0.120 |
Why?
|
| Single-Blind Method | 2 | 2013 | 111 | 0.120 |
Why?
|
| Phenylcarbamates | 1 | 2014 | 1 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 507 | 0.120 |
Why?
|
| Affect | 1 | 2014 | 62 | 0.120 |
Why?
|
| Genetic Markers | 2 | 2011 | 48 | 0.110 |
Why?
|
| Automation | 1 | 2014 | 9 | 0.110 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 623 | 0.110 |
Why?
|
| Discriminant Analysis | 1 | 2013 | 9 | 0.110 |
Why?
|
| Imagination | 1 | 2013 | 3 | 0.110 |
Why?
|
| Neurotransmitter Agents | 1 | 2013 | 17 | 0.110 |
Why?
|
| Physical Education and Training | 1 | 2013 | 5 | 0.110 |
Why?
|
| Neuroprotective Agents | 1 | 2014 | 55 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 180 | 0.110 |
Why?
|
| Functional Neuroimaging | 3 | 2018 | 7 | 0.110 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 90 | 0.110 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2013 | 67 | 0.110 |
Why?
|
| Hand | 2 | 2021 | 40 | 0.110 |
Why?
|
| Early Medical Intervention | 1 | 2013 | 15 | 0.100 |
Why?
|
| Atrophy | 1 | 2013 | 94 | 0.100 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2013 | 81 | 0.100 |
Why?
|
| Somatosensory Disorders | 1 | 2012 | 11 | 0.100 |
Why?
|
| Time Perception | 1 | 2012 | 6 | 0.100 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2012 | 29 | 0.100 |
Why?
|
| Image Enhancement | 1 | 2012 | 49 | 0.100 |
Why?
|
| Physical Endurance | 3 | 2016 | 8 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2012 | 70 | 0.100 |
Why?
|
| Frail Elderly | 2 | 2023 | 53 | 0.100 |
Why?
|
| Odds Ratio | 4 | 2017 | 269 | 0.100 |
Why?
|
| Biosensing Techniques | 1 | 2011 | 11 | 0.100 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2012 | 96 | 0.100 |
Why?
|
| Probability | 2 | 2009 | 92 | 0.090 |
Why?
|
| Musculoskeletal Physiological Phenomena | 1 | 2011 | 2 | 0.090 |
Why?
|
| Prevalence | 4 | 2014 | 467 | 0.090 |
Why?
|
| Muscles | 1 | 1991 | 57 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2011 | 135 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2021 | 373 | 0.090 |
Why?
|
| Outpatients | 2 | 2008 | 59 | 0.090 |
Why?
|
| Computer Systems | 1 | 2009 | 7 | 0.080 |
Why?
|
| Self-Help Devices | 1 | 2009 | 5 | 0.080 |
Why?
|
| Musculoskeletal System | 1 | 2009 | 7 | 0.080 |
Why?
|
| Electric Stimulation | 1 | 1990 | 53 | 0.080 |
Why?
|
| Consensus | 2 | 2021 | 98 | 0.080 |
Why?
|
| Baltimore | 3 | 2018 | 9 | 0.080 |
Why?
|
| Biophysical Phenomena | 1 | 2009 | 30 | 0.080 |
Why?
|
| Sampling Studies | 1 | 2009 | 30 | 0.080 |
Why?
|
| Color Perception | 1 | 2009 | 5 | 0.080 |
Why?
|
| Self-Assessment | 1 | 2009 | 30 | 0.080 |
Why?
|
| Normal Distribution | 2 | 2003 | 5 | 0.080 |
Why?
|
| Peroneal Nerve | 1 | 2009 | 5 | 0.080 |
Why?
|
| Semantics | 1 | 2009 | 19 | 0.080 |
Why?
|
| Israel | 1 | 2009 | 17 | 0.080 |
Why?
|
| Organ Size | 2 | 2020 | 106 | 0.080 |
Why?
|
| Gait Apraxia | 1 | 2008 | 1 | 0.080 |
Why?
|
| Pattern Recognition, Visual | 1 | 2009 | 27 | 0.080 |
Why?
|
| Chi-Square Distribution | 2 | 2007 | 146 | 0.080 |
Why?
|
| Psychological Tests | 1 | 2008 | 53 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 308 | 0.080 |
Why?
|
| Perception | 1 | 2009 | 78 | 0.080 |
Why?
|
| Arthralgia | 1 | 2009 | 125 | 0.070 |
Why?
|
| Interpersonal Relations | 1 | 2009 | 104 | 0.070 |
Why?
|
| Radio Waves | 1 | 2008 | 9 | 0.070 |
Why?
|
| Perceptual Masking | 1 | 2008 | 12 | 0.070 |
Why?
|
| Vocabulary | 1 | 2008 | 13 | 0.070 |
Why?
|
| Attitude | 1 | 2008 | 36 | 0.070 |
Why?
|
| Leg | 2 | 2005 | 53 | 0.070 |
Why?
|
| Genotype | 2 | 2022 | 359 | 0.070 |
Why?
|
| Peripheral Nervous System | 1 | 2007 | 1 | 0.070 |
Why?
|
| Apraxias | 1 | 2007 | 1 | 0.070 |
Why?
|
| Visual Cortex | 1 | 2007 | 6 | 0.070 |
Why?
|
| Psychophysiology | 1 | 2007 | 6 | 0.070 |
Why?
|
| Veterans Disability Claims | 1 | 2007 | 1 | 0.070 |
Why?
|
| Trauma Severity Indices | 1 | 2007 | 10 | 0.070 |
Why?
|
| Parietal Lobe | 1 | 2007 | 18 | 0.070 |
Why?
|
| Gyrus Cinguli | 1 | 2007 | 17 | 0.070 |
Why?
|
| Psychotropic Drugs | 1 | 2007 | 28 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 239 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2009 | 300 | 0.070 |
Why?
|
| Anxiety | 1 | 2008 | 161 | 0.070 |
Why?
|
| Verbal Behavior | 1 | 2007 | 18 | 0.070 |
Why?
|
| Dementia, Vascular | 1 | 2007 | 45 | 0.070 |
Why?
|
| Visual Perception | 1 | 2007 | 34 | 0.070 |
Why?
|
| Hippocampus | 2 | 2020 | 283 | 0.070 |
Why?
|
| Choice Behavior | 1 | 2007 | 47 | 0.070 |
Why?
|
| Systole | 3 | 2002 | 18 | 0.070 |
Why?
|
| Oscillometry | 2 | 2003 | 5 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2019 | 467 | 0.060 |
Why?
|
| Anthropometry | 1 | 2005 | 36 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2014 | 3615 | 0.060 |
Why?
|
| Neoplasms | 2 | 2001 | 241 | 0.060 |
Why?
|
| Extrapyramidal Tracts | 1 | 2005 | 1 | 0.060 |
Why?
|
| Urinary Incontinence | 1 | 2005 | 23 | 0.060 |
Why?
|
| Immobilization | 1 | 2004 | 14 | 0.060 |
Why?
|
| Fourier Analysis | 2 | 1995 | 8 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2005 | 80 | 0.060 |
Why?
|
| Confidence Intervals | 2 | 2017 | 97 | 0.060 |
Why?
|
| Mass Screening | 2 | 2005 | 184 | 0.060 |
Why?
|
| Meditation | 1 | 2004 | 23 | 0.060 |
Why?
|
| Emotions | 2 | 2002 | 87 | 0.050 |
Why?
|
| Multiple System Atrophy | 1 | 2004 | 38 | 0.050 |
Why?
|
| Heart Diseases | 2 | 1995 | 70 | 0.050 |
Why?
|
| Receptors, CCR5 | 1 | 2022 | 14 | 0.050 |
Why?
|
| Protective Factors | 1 | 2022 | 26 | 0.050 |
Why?
|
| Gene Frequency | 1 | 2022 | 63 | 0.050 |
Why?
|
| Photic Stimulation | 1 | 2002 | 35 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 19 | 0.050 |
Why?
|
| Negotiating | 1 | 2022 | 4 | 0.050 |
Why?
|
| ROC Curve | 2 | 2017 | 145 | 0.050 |
Why?
|
| Seizures | 1 | 2023 | 65 | 0.050 |
Why?
|
| Respiratory Mechanics | 1 | 2002 | 9 | 0.050 |
Why?
|
| Disease | 1 | 2002 | 6 | 0.050 |
Why?
|
| Oxyhemoglobins | 1 | 2021 | 1 | 0.050 |
Why?
|
| Massachusetts | 1 | 2001 | 19 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2023 | 205 | 0.050 |
Why?
|
| Physician's Role | 1 | 2001 | 19 | 0.050 |
Why?
|
| Weight Lifting | 1 | 2001 | 9 | 0.050 |
Why?
|
| Doxorubicin | 2 | 2001 | 55 | 0.050 |
Why?
|
| Pain | 2 | 2022 | 405 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2020 | 5 | 0.050 |
Why?
|
| Blood Flow Velocity | 1 | 2020 | 20 | 0.050 |
Why?
|
| Drug Therapy | 1 | 2000 | 9 | 0.040 |
Why?
|
| Physiology | 1 | 2000 | 4 | 0.040 |
Why?
|
| Databases as Topic | 1 | 2000 | 15 | 0.040 |
Why?
|
| Afferent Pathways | 1 | 2020 | 4 | 0.040 |
Why?
|
| Arousal | 1 | 2000 | 50 | 0.040 |
Why?
|
| Self Concept | 1 | 2000 | 43 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2001 | 372 | 0.040 |
Why?
|
| Leukocytosis | 1 | 2000 | 4 | 0.040 |
Why?
|
| Epilepsies, Partial | 1 | 1999 | 13 | 0.040 |
Why?
|
| Leukoencephalopathies | 1 | 2019 | 12 | 0.040 |
Why?
|
| Mortality | 1 | 2020 | 90 | 0.040 |
Why?
|
| Systems Analysis | 1 | 2019 | 4 | 0.040 |
Why?
|
| Fitness Trackers | 1 | 2019 | 14 | 0.040 |
Why?
|
| Device Approval | 1 | 2019 | 4 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 51 | 0.040 |
Why?
|
| Respiration | 3 | 2004 | 35 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2019 | 27 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 1999 | 45 | 0.040 |
Why?
|
| Internet | 1 | 2000 | 98 | 0.040 |
Why?
|
| Computer Security | 1 | 2019 | 6 | 0.040 |
Why?
|
| Neutrophils | 1 | 2000 | 110 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 352 | 0.040 |
Why?
|
| Body Height | 1 | 1999 | 37 | 0.040 |
Why?
|
| Animals | 5 | 2017 | 3814 | 0.040 |
Why?
|
| Models, Neurological | 1 | 2019 | 25 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2017 | 437 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 58 | 0.040 |
Why?
|
| Trail Making Test | 1 | 2018 | 4 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2000 | 147 | 0.040 |
Why?
|
| Random Allocation | 1 | 2018 | 130 | 0.040 |
Why?
|
| Globus Pallidus | 1 | 2018 | 11 | 0.040 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2018 | 4 | 0.040 |
Why?
|
| Support Vector Machine | 1 | 2018 | 7 | 0.040 |
Why?
|
| Nucleus Accumbens | 1 | 2018 | 14 | 0.040 |
Why?
|
| Glucosylceramidase | 1 | 2018 | 17 | 0.040 |
Why?
|
| White Matter | 1 | 2020 | 142 | 0.040 |
Why?
|
| Visual Acuity | 1 | 2018 | 39 | 0.040 |
Why?
|
| Muscle Strength | 1 | 2019 | 138 | 0.040 |
Why?
|
| Recombination, Genetic | 1 | 1997 | 6 | 0.040 |
Why?
|
| Amygdala | 1 | 2018 | 42 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 1997 | 10 | 0.040 |
Why?
|
| Genome | 1 | 1997 | 10 | 0.040 |
Why?
|
| Vincristine | 1 | 1997 | 21 | 0.040 |
Why?
|
| Women's Health | 1 | 1999 | 176 | 0.040 |
Why?
|
| Memory, Short-Term | 1 | 2018 | 103 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2018 | 84 | 0.040 |
Why?
|
| Intelligence Tests | 1 | 2017 | 15 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 1997 | 51 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2017 | 15 | 0.040 |
Why?
|
| Prednisone | 1 | 1997 | 65 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2017 | 65 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2018 | 92 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1997 | 35 | 0.030 |
Why?
|
| Oxygen | 1 | 2017 | 81 | 0.030 |
Why?
|
| Family | 1 | 2018 | 115 | 0.030 |
Why?
|
| Femur Neck | 1 | 2017 | 21 | 0.030 |
Why?
|
| Pressure | 1 | 2017 | 64 | 0.030 |
Why?
|
| Child, Preschool | 1 | 1999 | 692 | 0.030 |
Why?
|
| Liver | 1 | 1997 | 160 | 0.030 |
Why?
|
| Musculoskeletal Diseases | 1 | 1997 | 46 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 35 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2016 | 31 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 207 | 0.030 |
Why?
|
| Osteoporosis | 1 | 2017 | 77 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 1995 | 13 | 0.030 |
Why?
|
| Norepinephrine | 1 | 1995 | 30 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2016 | 152 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1995 | 35 | 0.030 |
Why?
|
| Markov Chains | 1 | 1995 | 32 | 0.030 |
Why?
|
| Genetic Code | 1 | 1994 | 1 | 0.030 |
Why?
|
| DNA Replication | 1 | 1994 | 10 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 1995 | 170 | 0.030 |
Why?
|
| Morphogenesis | 1 | 1994 | 8 | 0.030 |
Why?
|
| Rivastigmine | 1 | 2014 | 1 | 0.030 |
Why?
|
| Skin | 1 | 1995 | 115 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2009 | 442 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 111 | 0.030 |
Why?
|
| Palliative Care | 1 | 1995 | 109 | 0.030 |
Why?
|
| HIV Infections | 1 | 1999 | 490 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 1992 | 58 | 0.030 |
Why?
|
| Models, Genetic | 1 | 1992 | 42 | 0.030 |
Why?
|
| DNA | 1 | 1992 | 104 | 0.030 |
Why?
|
| Phenotype | 1 | 2013 | 311 | 0.030 |
Why?
|
| Coronary Disease | 1 | 1992 | 66 | 0.020 |
Why?
|
| Sample Size | 1 | 2011 | 20 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2011 | 31 | 0.020 |
Why?
|
| Age Distribution | 2 | 2004 | 89 | 0.020 |
Why?
|
| Sex Distribution | 2 | 2004 | 82 | 0.020 |
Why?
|
| Diastole | 2 | 2002 | 32 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2012 | 359 | 0.020 |
Why?
|
| Ankle Joint | 1 | 2010 | 45 | 0.020 |
Why?
|
| Clothing | 1 | 2009 | 3 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2009 | 13 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 2009 | 25 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2009 | 74 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 183 | 0.020 |
Why?
|
| Forecasting | 2 | 2000 | 103 | 0.020 |
Why?
|
| Homocysteine | 1 | 2005 | 8 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 166 | 0.020 |
Why?
|
| Cholesterol | 1 | 2005 | 64 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2005 | 91 | 0.010 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2004 | 5 | 0.010 |
Why?
|
| High-Frequency Ventilation | 1 | 2004 | 2 | 0.010 |
Why?
|
| Electromyography | 1 | 2004 | 71 | 0.010 |
Why?
|
| Rest | 1 | 2004 | 33 | 0.010 |
Why?
|
| Hip Joint | 1 | 2010 | 549 | 0.010 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 1995 | 46 | 0.010 |
Why?
|
| Physical Examination | 1 | 2004 | 119 | 0.010 |
Why?
|
| Speech Disorders | 1 | 2003 | 11 | 0.010 |
Why?
|
| Base Sequence | 2 | 1994 | 108 | 0.010 |
Why?
|
| Motion | 1 | 2003 | 22 | 0.010 |
Why?
|
| Videotape Recording | 1 | 2003 | 29 | 0.010 |
Why?
|
| Alabama | 1 | 2002 | 1 | 0.010 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2002 | 3 | 0.010 |
Why?
|
| Lung Volume Measurements | 1 | 2002 | 4 | 0.010 |
Why?
|
| Cyclosporins | 1 | 2001 | 3 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 2001 | 11 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2001 | 38 | 0.010 |
Why?
|
| Safety | 1 | 2001 | 45 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2001 | 51 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2001 | 44 | 0.010 |
Why?
|
| Body Weight | 1 | 2001 | 145 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2002 | 141 | 0.010 |
Why?
|
| Self Administration | 1 | 2000 | 22 | 0.010 |
Why?
|
| Subliminal Stimulation | 1 | 2000 | 1 | 0.010 |
Why?
|
| Internal-External Control | 1 | 2000 | 17 | 0.010 |
Why?
|
| Research | 1 | 2000 | 43 | 0.010 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2000 | 13 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2000 | 66 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2001 | 166 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 1999 | 71 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1997 | 43 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 1999 | 121 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 1997 | 59 | 0.010 |
Why?
|
| Anemia | 1 | 1999 | 94 | 0.010 |
Why?
|
| Length of Stay | 1 | 2000 | 330 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 1997 | 107 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 1997 | 228 | 0.010 |
Why?
|
| Least-Squares Analysis | 1 | 1995 | 8 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1995 | 37 | 0.010 |
Why?
|
| Supine Position | 1 | 1995 | 22 | 0.010 |
Why?
|
| Bias | 1 | 1995 | 41 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 1995 | 53 | 0.010 |
Why?
|
| Death, Sudden, Cardiac | 1 | 1995 | 14 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 1995 | 43 | 0.010 |
Why?
|
| Survival Rate | 1 | 1995 | 356 | 0.010 |
Why?
|
| Cardiac Output, Low | 1 | 1993 | 3 | 0.010 |
Why?
|
| Mice | 1 | 1997 | 1467 | 0.010 |
Why?
|
| Myosins | 1 | 1992 | 3 | 0.010 |
Why?
|
| Caenorhabditis elegans | 1 | 1992 | 6 | 0.010 |
Why?
|
| Introns | 1 | 1992 | 16 | 0.010 |
Why?
|
| Biological Evolution | 1 | 1992 | 10 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1992 | 27 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1992 | 8 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1993 | 71 | 0.010 |
Why?
|
| Chickens | 1 | 1992 | 36 | 0.010 |
Why?
|
| Rats | 1 | 1992 | 684 | 0.010 |
Why?
|